Anshika Jain
Two individuals can consume the same probiotic strain and experience very different outcomes. One person may show measurable changes in the gut microbiome or symptoms, while another may show little detectable response. Differences in age, health history, diet, medications, genetics, existing microbiome composition, and intestinal environment can all contribute to this variability. The U.S. National Center for Complementary and Integrative Health has identified this person-to-person variation as a major research challenge and has supported efforts to understand the biological factors behind different probiotic responses.
This has led researchers toward an emerging concept known as precision probiotics. Instead of assuming that one probiotic formulation should work broadly across an entire population, precision approaches investigate whether specific strains, combinations, doses, or formulations could be matched to particular biological characteristics.
The idea represents a broader transformation in microbiome research. Rather than treating the gut microbiome as a single system that can be improved through a universal intervention, scientists are increasingly investigating the individual ecosystem of each person. The ultimate question is whether future microbiome therapies could be selected or designed according to an individual’s microbial, metabolic, physiological, and clinical profile.
What Are Precision Probiotics?
Precision probiotics can be understood as a developing approach in which probiotic interventions are selected or designed according to characteristics of the recipient, the intended health outcome, and the biological activity of particular microbial strains.
Traditional probiotic products may contain one or more microorganisms selected because previous research has associated them with a particular health benefit. Precision approaches take the concept further by asking whether a person’s existing microbiome and biological environment influence whether that microorganism can survive, interact with resident microbes, produce relevant metabolites, or generate a measurable host response.
Recent research describes two complementary directions within this emerging field. One involves stratified probiotics, in which specific formulations are designed for groups of people who share relevant biological characteristics. The other involves more individualised probiotic strategies that use personal microbial and physiological information to guide intervention choices.
The distinction is important because truly individualised therapy is considerably more complex than simply recommending a different probiotic to different people. It requires reliable biomarkers, detailed biological information, validated prediction models, and clinical evidence showing that personalised selection actually improves outcomes.
Why Conventional Probiotics Can Produce Different Results
The human gut is an ecosystem containing thousands of microbial populations interacting with one another and with the host. Introducing a probiotic microorganism into this environment does not occur in isolation.
A probiotic strain entering the gastrointestinal tract encounters existing bacteria, available nutrients, digestive conditions, bile acids, immune signals, and other environmental factors. Whether the organism can remain detectable, interact with resident microorganisms, or produce a desired biological effect may therefore depend on the environment it enters.
Diet can be particularly important. Food provides substrates that gut microorganisms use to produce metabolites, and differences in dietary patterns can alter the ecological conditions in which a probiotic strain operates. Medications, including antibiotics, can also alter microbial communities and potentially change how an introduced microorganism behaves.
Health status and the existing microbiome may be equally important. A person with an intestinal environment that already supports a particular microbial function may respond differently from someone whose microbiome has a different metabolic capacity.
This complexity helps explain why conventional probiotic studies can produce inconsistent results. Research from the NIH has specifically highlighted differences in gut microbiota, diet, age, lifestyle, health history, and other person-specific characteristics as possible contributors to variable probiotic responses.
The Microbiome as a Personal Biological Ecosystem
One of the foundations of precision probiotics is the recognition that the microbiome differs substantially between individuals. Although people share broad microbial functions, the exact composition and activity of their gut ecosystems can vary.
This variation means that a probiotic strain that performs well in one individual may not behave identically in another. The resident microbial community can influence whether an introduced microorganism can establish itself, compete for nutrients, interact with other bacteria, or produce specific metabolites.
For precision medicine, this variation is not simply an inconvenience. It can become useful information.
Researchers can potentially examine microbial composition, microbial genes, metabolic pathways, and host characteristics to identify patterns associated with treatment response. The objective is to transform biological variation from an unexplained source of inconsistent outcomes into information that can guide treatment selection.
Recent reviews describe the integration of microbiome data with host characteristics and environmental factors as an important direction for developing more precise probiotic therapies.
From Microbial Names to Microbial Functions
An important development in microbiome science is the shift from focusing exclusively on which organisms are present toward understanding what those organisms actually do.
Two individuals can have different bacterial species but share some important microbial functions. Conversely, two people may contain similar microbial organisms that behave differently because their surrounding environments are different.
This means that precision probiotics may eventually be selected according to functional characteristics rather than simply microbial names. Researchers could look for strains capable of producing particular metabolites, interacting with specific pathways, supporting intestinal barrier functions, or influencing defined biological processes.
This functional perspective is particularly relevant because microbial metabolites can affect host physiology. Short-chain fatty acids, bile-acid transformations, and other microbial products can interact with intestinal cells, immune pathways, and metabolic systems.
The future of probiotic development may therefore involve identifying strains according to the biological functions they can deliver and determining which individuals are most likely to benefit from those functions.
The Role of Multi-Omics
Precision probiotic research requires more information than conventional microbiome sequencing alone can provide. This is where multi-omics approaches become increasingly important.
Metagenomics can provide information about microbial genes. Metatranscriptomics can help researchers investigate which genes are actively expressed. Metabolomics can identify molecules produced or modified by microbial and host processes. Proteomics can provide information about proteins involved in biological pathways.
Combining these layers could create a more detailed picture of the relationship between a person and their microbiome.
For example, researchers may eventually be able to determine that a particular individual lacks or underproduces a specific microbial function, identify a bacterial strain capable of supporting that function, and then determine whether the person’s intestinal environment is suitable for that strain.
Such an approach would move probiotic research closer to a biological matching system rather than a general supplementation model.
Artificial Intelligence and Probiotic Selection
The complexity of the microbiome makes computational analysis increasingly important. A single individual can generate enormous amounts of genomic, metabolic, clinical, dietary, and longitudinal data.
Artificial intelligence and machine learning could help identify patterns that are difficult to detect through conventional analysis. Researchers can potentially use computational models to examine which combinations of host characteristics and microbial features are associated with probiotic response.
The NIH has explicitly identified computational and AI approaches as relevant to precision probiotic research, particularly for identifying person-specific factors and potential responder subgroups.
However, AI prediction is not the same as clinical validation. A model may identify an association in a dataset without proving that the predicted probiotic will work in an individual patient. Experimental research and carefully designed clinical trials remain essential.
The most useful role for AI may therefore be as a tool that helps researchers generate and test biological hypotheses rather than as an independent decision-maker.
Designing Probiotics Around Specific Health Problems
Precision probiotics may eventually become more closely connected with specific health conditions. Rather than marketing a general product for broad “gut health,” researchers could investigate microbial interventions designed around particular biological deficits.
For example, a therapy could theoretically target a microbial function associated with intestinal barrier regulation, inflammation, metabolite production, or pathogen resistance. The appropriate strain or combination could then be selected according to the patient’s biological profile.
This concept is already influencing microbiome therapeutics research more broadly. A 2025 review in Nature Medicine described the growing clinical translation of microbiome science, including microbiome-based diagnostics and therapeutics and the use of microbial measurements to support precision medicine and personalised healthcare.
The field is therefore moving toward a model in which microbial interventions are evaluated according to mechanism, patient characteristics, and clinical outcomes rather than broad assumptions about the microbiome.
Single Strains Versus Microbial Consortia
A future precision probiotic therapy may not necessarily consist of one bacterial strain. Some biological functions may require interactions between multiple microorganisms.
Researchers are therefore investigating defined bacterial consortia, in which carefully selected microorganisms are combined to perform complementary functions. The goal is to create a more predictable microbial community rather than relying on a complex and poorly defined mixture.
This approach introduces additional complexity. Researchers must determine how the organisms interact, whether they can coexist, how they respond to the patient’s existing microbiome, and whether the combination remains stable during manufacturing and administration.
The possibility of designing microbial consortia is nevertheless important because the microbiome itself functions as an ecosystem. In some circumstances, reproducing a particular biological function may require cooperation between several microorganisms.
Personalised Nutrition Could Become Part of the Therapy
Precision probiotics may also become increasingly connected with personalised nutrition. A probiotic microorganism requires an environment in which it can function, and dietary inputs can influence that environment.
Researchers are investigating how diet, prebiotics, and probiotics interact and whether microbiome characteristics can help predict responses to dietary interventions. A recent randomized trial involving 802 people with prediabetes investigated whether gut microbiome characteristics could predict individual responses to a dietary fibre intervention, illustrating the broader movement toward microbiome-informed personalised nutrition.
In a future precision model, the intervention may therefore involve more than taking a microbial supplement. Dietary changes could provide substrates that support the intended microbial activity, while the probiotic supplies a particular strain or function.
This could create a more integrated approach in which microbial therapy and nutrition are designed together.
The Importance of Colonisation and Engraftment
One of the major questions in probiotic research is whether a probiotic microorganism needs to permanently colonise the gut to produce a beneficial effect.
The answer may depend on the strain and the intended function. Some microorganisms may exert effects while they are temporarily present, whereas others may need to persist or interact repeatedly with the intestinal environment.
Researchers have therefore begun studying colonisation and engraftment more carefully. The NIH’s precision probiotic workshop identified colonisation and engraftment as important considerations while also noting that permanent colonisation is not necessarily essential for every microbial therapeutic.
Understanding this distinction could influence how future therapies are designed. Instead of asking whether a probiotic permanently changes the microbiome, researchers may focus on whether it produces a specific biological effect for a clinically meaningful period.
Personalised Probiotics Are Still an Emerging Research Field
Despite the enthusiasm surrounding precision probiotics, it is important to recognise that personalised probiotic medicine is not yet a routine clinical reality.
A major challenge is the lack of universally validated biomarkers that can reliably predict who will respond to a particular probiotic. Researchers also need larger and more diverse clinical studies that account for differences in diet, medication, genetics, microbiome composition, age, geography, and health status.
Another challenge is standardisation. Probiotic effects can depend on the exact strain rather than merely the species name. Dosage, formulation, viability, manufacturing conditions, and storage can also influence the final product.
Recent reviews continue to identify variability in clinical outcomes, limited mechanistic understanding, standardisation problems, and the need for stronger clinical evidence as major barriers to widespread precision probiotic applications.
These challenges mean that personalised probiotics should currently be viewed as an active area of research rather than an established replacement for conventional medical treatment.
Safety and Regulatory Considerations
Personalised microbial therapies would also require rigorous safety evaluation. Introducing microorganisms into a person’s body involves questions about strain identity, genetic characteristics, potential interactions with the existing microbiome, antimicrobial resistance, immune effects, and manufacturing quality.
These concerns become even more important when researchers consider engineered microorganisms or complex bacterial consortia.
The regulatory pathway for microbiome-based therapies is also developing. Unlike ordinary foods or dietary supplements, therapeutic microbial products intended to treat specific diseases may require pharmaceutical-style evidence regarding manufacturing, safety, efficacy, and consistency.
As microbiome therapeutics become more sophisticated, regulatory systems will need methods for evaluating products whose biological activity depends on interactions between multiple microorganisms and an individual host.
The Future: From Personalised Probiotics to Microbiome Engineering
The long-term vision of precision probiotics extends beyond choosing one commercial supplement over another. It could eventually involve engineering microbial ecosystems around specific biological objectives.
Researchers are exploring technologies such as organoids, organ-on-a-chip systems, computational modelling, advanced delivery systems, and genetic engineering to understand and potentially improve microbial therapeutics. Emerging research also considers whether microbial combinations can be rationally designed to support colonisation and specific functions.
A future therapy might therefore begin with a detailed patient profile. Microbiome sequencing could describe microbial composition, metabolomics could identify functional outputs, clinical data could define the health problem, and computational models could predict which microbial intervention is most appropriate.
The patient could then receive a precisely characterised microbial preparation accompanied by a nutritional or behavioural plan designed to support its intended function.
Such a system remains a future possibility rather than an established clinical workflow, but it illustrates how microbiome research is moving toward increasingly targeted interventions.
Conclusion
Precision probiotics represent a significant evolution in the way scientists think about probiotic therapy. Instead of assuming that the same microorganism should produce the same outcome in every person, researchers are investigating how individual differences in microbiomes, physiology, diet, genetics, medications, and health status influence microbial responses.
The central idea is relatively simple: if people have different microbial ecosystems, microbiome-based therapies may eventually need to account for those differences.
Advances in metagenomics, metabolomics, multi-omics, artificial intelligence, microbial engineering, and personalised nutrition are creating new opportunities to investigate this possibility. Research organisations such as the NIH are already supporting mechanistic studies aimed at identifying the person-specific factors that influence probiotic response.
At the same time, substantial scientific challenges remain. Researchers need reliable biomarkers, reproducible microbial preparations, larger clinical trials, stronger mechanistic evidence, and clear safety and regulatory frameworks. A microbiome profile alone cannot yet determine which probiotic a particular patient should receive.
The future of microbiome medicine may ultimately involve a shift from general supplementation toward targeted microbial interventions. Instead of asking whether probiotics work in general, researchers may increasingly ask which strain works, for which person, under which biological conditions, at what dose, and for what specific outcome.
If these questions can be answered through rigorous research, precision probiotics could become part of a broader generation of microbiome-based therapies designed around individual biological differences. The goal would not simply be to add more bacteria to the gut, but to understand the ecosystem well enough to influence specific functions in a controlled and clinically meaningful way.